Anticipate Testing of New Pediatric Formulations of XEN496 and XEN901 in Adults in Third Quarter,  Followed by IND Submissions to Initiate Pediatric Clinical Trials in   KCNQ2 and SCN8A Developmental and Epileptic Encephalopathies Conference Call at 4:30 pm ET Today BURNABY, British Columbia , Aug. ...

BURNABY, British Columbia , July 31, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2019 financial and operating results after the close of U.S. ...

Company Highlights Recent Regulatory Feedback Guiding the Clinical Development of XEN901  into Pediatric SCN8A-EE Patients Webcast of Conference Presentation at 11:00 am ET Today BURNABY, British Columbia , June 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. ...

BURNABY, British Columbia , May 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Officer, will present a corporate update at the Jefferies 2019 Healthcare Conference ...

Company Reports Advancements in Neurology-Focused Pipeline and Anticipates Multiple Products in  Phase 2 or Later Stage Development this Year Conference Call at 4:30 pm ET Today BURNABY, British Columbia , May 07, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. ...

BURNABY, British Columbia , April 30, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2019 financial and operating results after the close of U.S. ...

BURNABY, British Columbia , April 24, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. ...

Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia , March 06, 2019 (GLOBE NEWSWIRE) -- Xenon ...

BURNABY, British Columbia , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019 . ...

Behind the Seizure™ Program Expansion Helps Speed the Diagnosis  of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures — Stoke Therapeutics and Xenon Pharmaceuticals Join  Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing  Program for Children Up to 60 ...

FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2b Clinical Trial ...

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia , Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided ...